Takeda Pharmaceutical Company Limited (TAK) has been center of attention due to various factors. There is an investors attraction due to the stock being undervalued and offering a high-yield dividend, sparking interest among value and dividend investors.
Creative Planning, a notable investment firm, increased its stakes in TAK, although later sold some shares. Takeda's ADHD drug production saw a boost due to US approval. However, the company faced
profit decline in FY23, and the performance seems volatile with a 5.9% decrease in 4 weeks, inspiring discussions about a potential turnaround. Takeda also issued FY24 earnings guidance and beat Q1 2025 earnings expectations. Despite potential risks associated with its use of debt, TAK still seems appealing, as indicated by hedge fund bullishness. Partnering with companies like
Lupin and
Torrent Pharmaceuticals, TAK has been expanding its reach in the Indian pharmaceutical sector. New initiatives like an employee incentive plan have been unveiled. Nevertheless, the company chose to withdraw a lung cancer therapy, and FY forecasts have been slashed due to drug pipeline impairments.
Takeda Pharmaceutical Stocks News Analytics from Mon, 09 Jan 2017 08:00:00 GMT to Thu, 31 Oct 2024 13:00:56 GMT -
Rating 2
- Innovation -5
- Information 7
- Rumor -1
